Saturday - July 12, 2025
NIH Issues Notice on Prospective Exclusive Patent License for Anti-CD19 Chimeric Antigen Receptor Therapy
July 10, 2025
WASHINGTON, July 10 (TNSFR) -- The U.S. Department of Health and Human Services National Institutes of Health has issued a notice entitled "Prospective Grant of an Exclusive Patent License: Development of an in vivo Anti-CD19 Chimeric Antigen Receptor for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases."

The notice announces that the National Cancer Institute is considering granting an exclusive patent license to Capstan Therapeutics Inc., San Diego, Cal . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products